Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TNF | P01375 | 7/20 | 0.47 |
| ▸ | MMP13 | P45452 | 8/20 | 0.45 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6704440 | 0.90 | TNF (0.59) | KDM4EALDH1A1TNFMMP13SLC22A8 | |
| SCHEMBL6180019 | 0.90 | MMP13 (0.51) | KDM4EMMP13SLC22A8CYP3A4CYP2C9 | |
| SCHEMBL6175431 | 0.88 | TNF (0.64) | TNFMMP13 | |
| SCHEMBL6179275 | 0.88 | TNF (0.61) | TNFMMP13SLC22A8 | |
| SCHEMBL6176297 | 0.87 | TNF (0.60) | TNFMMP13SLC22A8 | |
| SCHEMBL6171522 | 0.86 | MMP13 (0.46) | KDM4EMMP13SLC22A8CYP3A4CYP2C9 | |
| SCHEMBL6168287 | 0.83 | MMP13 (0.46) | KDM4EALDH1A1MMP13SLC22A8 | |
| SCHEMBL6182659 | 0.82 | MMP13 (0.49) | KDM4ETNFMMP13SLC22A8L3MBTL1 | |
| SCHEMBL6704396 | 0.80 | MMP13 (0.42) | KDM4ETNFMMP13SLC22A8 | |
| SCHEMBL6167249 | 0.80 | MMP13 (0.56) | MMP13SLC22A8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1530472-A1 | ISOQUINOLINE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2005-05-18 | — | — | EP | disclosed |
| US-20040044000-A1 | Isoquinoline derivatives as matrix metalloproteinase inhibitors | BUNKER AMY MAE (US) | 2004-03-04 | — | — | US | disclosed |
| WO-2004014379-A1 | ISOQUINOLINE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044000-A1 | Isoquinoline derivatives as matrix metalloproteinase inhibitors | MMP1, MMP13, MMP9 | KDM4E 1326/4885ALDH1A1 1297/4885TNF 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.